A<unk>  (DRI) is a class of drug which acts as a<unk>  inhibitor of the monoamine neurotransmitter<unk>  by blocking the action of the<unk>  transporter (DAT).<unk>  inhibition is achieved when extracellular<unk>  not absorbed by the postsynaptic neuron is blocked from re-entering the presynaptic neuron. This results in increased extracellular concentrations of<unk>  and increase in<unk> rgic neurotransmission. DRIs are used in the treatment of attention-deficit hyperactivity disorder (ADHD) and narcolepsy for their psychostimulant effects, and in the treatment of obesity and binge eating disorder for their appetite suppressant effects. They are sometimes used as antidepressants in the treatment of mood disorders, but their use as antidepressants is limited given that strong DRIs have a high abuse potential and legal restrictions on their use. Lack of<unk><unk>  and the increase in extracellular levels of<unk>  have been linked to increased susceptibility to addictive behavior given increase in<unk> rgic neurotransmission. The<unk> rgic pathways are considered to be strong reward centers. Many DRIs such as cocaine are drugs of abuse due to the rewarding effects evoked by elevated synaptic concentrations of<unk>  in the brain.
Dopamine reuptake inhibitor
Norepinephrine reuptake inhibitor
Glycine reuptake inhibitor
Monoamine reuptake inhibitor
Serotonin–dopamine reuptake inhibitor
Dopamine antagonist
Serotonin–norepinephrine reuptake inhibitor
GABA reuptake inhibitor